the-infoshop.com - The vertical markets research portal
View CartView Cart
Global Information, Inc.
US: +1-860-674-8796
EU: +32-2-535-7543
SG: +65-6223-2436
  Home | Category | Publishers | Custom Research | E-mail Alert | About Us | Contact Us | Site Map |
 

* View All Categories
View Conferences
Japanese Korean Chinese

Market Research Report

Trends in PCI - PCI vs. Thrombolysis: The Debate

Published by Datamonitor Contact us : +1-860-674-8796
Published 2004/12 Content info 31 Pages
Product code DC25946
Price From  US $ 1900 Order/Price list
US $ 1900 PDF by E-mail (Single User License)
US $ 4750 PDF by E-mail (Global License)
Delivery Time
PDF by E-Mail
Approx. 1-2 business days
Hard Copy/CD-ROM
Approx. 3-4 business days
If you need expedited delivery, please call us.
Description TOC

Introduction

  • Drug-eluting stents have become the gold standard in PCI procedures; it is up for debate as to whether biodegradable stents become the future gold standard. The debate about PCI vs thrombolysis still continues, however opinion seems to be falling firmly on the side of PCI.

Scope of this report

  • Market overview and review of the rise of drug eluting stents to gold-standard status, with an update on clinical trials and reimbursement status
  • Identify the key players in the PCI drug-eluting stent market and understand how this is likely to change with the advent of biodegradable stents
  • Follow the debate on PCI vs. thrombolysis and understand why opinion leaders seem to favor PCI
  • Understand the critical issue around time-to-needle and remote transfer

Research and analysis highlights

  • The drug-eluting stent seems to be the device for the future by solving (and promising to solve) one of the largest problems of interventional coronary treatment: restenosis. Opinion leaders interviewed by Datamonitor in 2004 suggest that the use of drug-eluting stents has reached 9095% of the stent market both in the US and Europe.
  • It is now thought that even with the additional delay, transfer of patients for PCI is associated with better outcomes than treating with thrombolysis at the local hospital.
  • When primary PCI cannot be provided readily and transfer is necessary, intravenous thrombolysis may be a better choice for patients seen early (within the first two hours), especially if it can be provided in a pre-hospital setting. This does not preclude subsequent transfer to an interventional center.

Key reasons to read this report

  • Understand the reasons for the success of drug-eluting stents and their rise to becoming the gold-standard treatment
  • Identify the key players in the PCI drug-eluting stent market and understand how the market will evolve with the advent of biodegradable stents
  • Understand why opinion leaders seem to favor PCI over thrombolysis and the critical issue around time-to-needle and remote transfer
Related Report
Back to Top
Please inform me when related publications are released
InfoWatch

US: 1-860-674-8796 EU: 32-2-535-7543 SG: 65-6223-2436
The vertical markets research portal
© 2009, the-infoshop.com by Global Information, Inc. All rights reserved.